Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response.
Zhang P. et al, (2021), Cancer Res
Targeting IGF perturbs global replication through ribonucleotide reductase dysfunction
Rieunier G. et al, (2021), Cancer Research, canres.2860.2020 - canres.2860.2020
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Wells CI. et al, (2021), International Journal of Molecular Sciences, 22, 566 - 566
The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers.
Lumley SF. et al, (2021), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Chapter 7: Public-Private Partnerships to Advance Phenotypic Drug Discovery
Carragher N. et al, (2021), RSC Drug Discovery Series, 2021-January, 118 - 139